Theme |
Precancerous Conditions and Cancer High-risk Lesions in the Colorectum |
Title |
Anal Canal Cancer |
Author |
Kazuhiro Watanabe |
Department of Surgery, Tohoku University Graduate School of Medicine |
Author |
Chikashi Shibata |
Department of Surgery, Tohoku University Graduate School of Medicine |
Author |
Koh Miura |
Department of Surgery, Tohoku University Graduate School of Medicine |
Author |
Takeshi Naito |
Department of Surgery, Tohoku University Graduate School of Medicine |
Author |
Hitoshi Ogawa |
Department of Surgery, Tohoku University Graduate School of Medicine |
Author |
Iwao Sasaki |
Department of Surgery, Tohoku University Graduate School of Medicine |
[ Summary ] |
Chemoradiation therapy with a combination of mitomycin C and 5-FU is the standard primary therapy for anal canal cancer in Europe and the United States, while, surgery (abdomino-perineal resection) is still the major therapy for anal canal cancer in Japan. JCOG0903 (A phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical stage II/III squamous cell carcinoma of the anal canal) has just started and we expect to produce evidence of the effectiveness of chemoradiotherapy for anal canal cancer in Japan. |